

Jaume Sastre-Garriga

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3156281/jaume-sastre-garriga-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

168 papers	6,920 citations	46 h-index	78 g-index
193 ext. papers	8,622 ext. citations	6.1 avg, IF	5.58 L-index

#	Paper	IF	Citations
168	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.. <i>Journal of Neurology</i> , 2022 , 269, 1764	5.5	0
167	Prognosis of a second clinical event from baseline MRI in patients with a CIS: a multicenter study using a machine learning approach.. <i>Neuroradiology</i> , 2022 , 1	3.2	
166	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022 , 9,	9.1	3
165	T1/T2-weighted ratio in multiple sclerosis: A longitudinal study with clinical associations.. <i>NeuroImage: Clinical</i> , 2022 , 34, 102967	5.3	0
164	Spinal cord grey matter atrophy in Multiple Sclerosis clinical practice. <i>Neuroscience Informatics</i> , 2022 , 100071		0
163	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221089540	5	1
162	Optic Nerve Topography in Multiple Sclerosis Diagnosis: The Utility of Visual Evoked Potentials. <i>Neurology</i> , 2021 , 96, e482-e490	6.5	6
161	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211053001	5	0
160	Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 2235	5.3	3
159	Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: A voxel-wise, multicentre analysis. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211045545	5	1
158	Adding brain volume measures into response criteria in multiple sclerosis: the RB-4 score. <i>Neuroradiology</i> , 2021 , 63, 1031-1041	3.2	0
157	Foveal changes in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder are independent of optic neuritis and not overtly progressive. <i>European Journal of Neurology</i> , 2021 , 28, 2280-2293 ⁵	6	5
156	Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset. <i>European Journal of Neurology</i> , 2021 ,	6	3
155	Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score. <i>European Journal of Neurology</i> , 2021 , 28, 2533-2542	6	3
154	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211010082	5	2
153	The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 968-972	5	2
152	COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. <i>European Journal of Neurology</i> , 2021 , 28, 3384-3395	6	60

151	Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study. <i>NeuroImage: Clinical</i> , 2021 , 29, 102549	5.3	6
150	Mind the gap: from neurons to networks to outcomes in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2021 , 17, 173-184	15	18
149	Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references. <i>NeuroImage: Clinical</i> , 2021 , 30, 102659	5.3	0
148	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 913-921	5	7
147	Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 989-1001	5	7
146	Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer. <i>Frontiers in Neurology</i> , 2021 , 12, 693333	4.1	1
145	Multiple sclerosis is associated with higher comorbidity and health care resource use: A population-based, case-control study in a western Mediterranean region. <i>European Journal of Neurology</i> , 2021 , 28, 4124-4134	6	1
144	2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. <i>Lancet Neurology</i> , 2021 , 20, 653-670	24.1	44
143	CSF Chitinase 3-Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	2
142	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. <i>Neurology</i> , 2021 , 97, e1641-e1652	6.5	6
141	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients. <i>Journal of Neurology</i> , 2021 , 1	5.5	3
140	Drug-related demyelinating syndromes: understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 55, 103146	4	0
139	Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis. <i>Neurology</i> , 2021 , 96, e1561-e1573	6.5	5
138	Ratio of T1-Weighted to T2-Weighted Signal Intensity as a Measure of Tissue Integrity: Comparison with Magnetization Transfer Ratio in Patients with Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2020 , 41, 461-463	4.4	6
137	EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis. <i>Journal of Palliative Medicine</i> , 2020 , 23, 1426-1443	2.2	4
136	Keeping standards of multiple sclerosis care through the COVID-19 pandemic. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1153-1156	5	13
135	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. <i>Nature Reviews Neurology</i> , 2020 , 16, 171-182	15	68
134	Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 388-391	5.5	8

133	A validation study of manual atrophy measures in patients with Multiple Sclerosis. <i>Neuroradiology</i> , 2020 , 62, 955-964	3.2	4
132	Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2020 , 41, 1001-1008	4.4	30
131	Multiple sclerosis management during the COVID-19 pandemic. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1163-1171	3.4	34
130	An Expert Patient Program as a Tool to Empower People With Multiple Sclerosis. <i>Journal of Neuroscience Nursing</i> , 2020 , 52, 166-171	1.5	1
129	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1658-1669	5	18
128	Longitudinal Assessment of Multiple Sclerosis with the Brain-Age Paradigm. <i>Annals of Neurology</i> , 2020 , 88, 93-105	9.4	26
127	The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020 , 6, 2055217320907951	2	1
126	Brain regional volume estimations with NeuroQuant and FIRST: a study in patients with a clinically isolated syndrome. <i>Neuroradiology</i> , 2019 , 61, 667-674	3.2	6
125	Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. <i>Neurology</i> , 2019 , 92, e1507-e1516	6.5	31
124	Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis. <i>European Journal of Neurology</i> , 2019 , 26, 41-50	6	14
123	Editorial. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1335-1336	5	2
122	Simultaneous CMV and infection following alemtuzumab treatment for multiple sclerosis. <i>Neurology</i> , 2019 , 92, 296-298	6.5	13
121	Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge. <i>Neurology</i> , 2019 , 92, 180-192	6.5	50
120	Multiple sclerosis registries in Europe - An updated mapping survey. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 27, 171-178	4	33
119	Treatment of multiple sclerosis - success from bench to bedside. <i>Nature Reviews Neurology</i> , 2019 , 15, 53-58	15	129
118	Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1383-1385	5	5
117	The role of the cerebellum in multiple sclerosis-150 years after Charcot. <i>Neuroscience and Biobehavioral Reviews</i> , 2018 , 89, 85-98	9	31
116	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. <i>Nature Reviews Neurology</i> , 2018 , 14, 199-213	15	95

115	The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. <i>Brain</i> , 2018 , 141, 1075-1084	11.2	64
114	Classic Block Design "Pseudo"-Resting-State fMRI Changes After a Neurorehabilitation Program in Patients with Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2018 , 28, 313-319	2.8	9
113	"Brain reserve" and "cognitive reserve" should always be taken into account when studying neurodegeneration - NO. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 576-577	5	
112	Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2018 , 39, 399-404	4.4	16
111	Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. <i>Nature Reviews Neurology</i> , 2018 , 14, 75-93	15	84
110	Deep gray matter volume loss drives disability worsening in multiple sclerosis. <i>Annals of Neurology</i> , 2018 , 83, 210-222	9.4	185
109	Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging. <i>Radiology</i> , 2018 , 288, 554-564	20.5	32
108	Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. <i>NeuroImage: Clinical</i> , 2018 , 19, 466-475	5.3	33
107	Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 721-727	5	3
106	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 301-312	5	55
105	Disability progression markers over 6-12 years in interferon- β -treated multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 322-330	5	45
104	Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 316-318	5.5	14
103	Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Commentary. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1539-1540	5	1
102	Myasthenia gravis following alemtuzumab therapy for multiple sclerosis. <i>Neurology</i> , 2018 , 91, 622-624	6.5	6
101	Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1843-1851	5	60
100	Risk knowledge of people with relapsing-remitting multiple sclerosis - Results of an international survey. <i>PLoS ONE</i> , 2018 , 13, e0208004	3.7	11
99	The hippocampus in multiple sclerosis. <i>Lancet Neurology, The</i> , 2018 , 17, 918-926	24.1	57
98	Progression of regional grey matter atrophy in multiple sclerosis. <i>Brain</i> , 2018 , 141, 1665-1677	11.2	146

97	Brain Atrophy in Multiple Sclerosis: Clinical Relevance and Technical Aspects. <i>Neuroimaging Clinics of North America</i> , 2017 , 27, 289-300	3	42
96	Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2017 , 38, 1486-1493	4.4	37
95	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. <i>Lancet Neurology</i> , 2017 , 16, 797-812	24.1	243
94	Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study. <i>NeuroImage</i> , 2017 , 163, 106-114	7.9	18
93	Lesion topographies in multiple sclerosis diagnosis: A reappraisal. <i>Neurology</i> , 2017 , 89, 2351-2356	6.5	19
92	Comparison between gadolinium-enhanced 2D T1-weighted gradient-echo and spin-echo sequences in the detection of active multiple sclerosis lesions on 3.0T MRI. <i>European Radiology</i> , 2017 , 27, 1361-1368	8	3
91	Grey matter atrophy is associated with disability increase in natalizumab-treated patients. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 556-566	5	17
90	Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images. <i>American Journal of Neuroradiology</i> , 2017 , 38, 250-256	4.4	6
89	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. <i>Neurology</i> , 2016 , 87, 1368-74	6.5	37
88	Multiple sclerosis: Dimethyl fumarate is coming of age. <i>Nature Reviews Neurology</i> , 2016 , 12, 436-7	15	4
87	Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics. <i>Journal of Neuroimaging</i> , 2016 , 26, 532-8	2.8	17
86	Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response. <i>Current Opinion in Neurology</i> , 2016 , 29, 254-62	7.1	37
85	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. <i>Lancet Neurology</i> , 2016 , 15, 292-303	24.1	486
84	An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 842-6	5	14
83	Lesion filling effect in regional brain volume estimations: a study in multiple sclerosis patients with low lesion load. <i>Neuroradiology</i> , 2016 , 58, 467-74	3.2	17
82	Highlights from the 31st ECTRIMS congress - Barcelona 2015. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 7-10	5	11
81	Longitudinal fMRI studies: Exploring brain plasticity and repair in MS. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 269-78	5	32
80	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1386-1396	5	83

79	Leptomeningeal enhancement in Susac syndrome and multiple sclerosis: Time to expect the unexpected?. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 975-6	5	5
78	Neurofilament light chain level is a weak risk factor for the development of MS. <i>Neurology</i> , 2016 , 87, 1076-84	6.5	61
77	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. <i>Brain</i> , 2015 , 138, 1863-74	11.2	302
76	Juxtacortical Lesions and Cortical Thinning in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2015 , 36, 2270-6	4.4	10
75	Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe. <i>Journal of the Neurological Sciences</i> , 2015 , 359, 146-50	3.2	6
74	Significant clinical worsening after natalizumab withdrawal: Predictive factors. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 780-5	5	37
73	Brain atrophy in natalizumab-treated patients: A 3-year follow-up. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 749-56	5	43
72	Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy. <i>Journal of Neurology</i> , 2015 , 262, 2617-26	5.5	28
71	Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1802-10	5	2
70	Predictive value of early brain atrophy on response in patients treated with interferon β . <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2015 , 2, e132	9.1	25
69	Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling. <i>NeuroImage: Clinical</i> , 2015 , 9, 640-7	5.3	19
68	Diagnosis and trials of clinically isolated syndrome. <i>Lancet Neurology</i> , 2014 , 13, 962-3	24.1	3
67	Multiple sclerosis registries in Europe - results of a systematic survey. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1523-32	5	43
66	Predictive markers of disease evolution after a CIS in everyday practice. <i>Journal of the Neurological Sciences</i> , 2014 , 343, 8-14	3.2	4
65	Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 72-80	5	81
64	Preliminary validation study of the Spanish version of the satisfaction with life scale in persons with multiple sclerosis. <i>Disability and Rehabilitation</i> , 2014 , 36, 1001-5	2.4	19
63	Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1602-8	5	33
62	Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. <i>Journal of Neuroinflammation</i> , 2014 , 11, 46	10.1	63

61	Localized grey matter atrophy in multiple sclerosis: a meta-analysis of voxel-based morphometry studies and associations with functional disability. <i>Neuroscience and Biobehavioral Reviews</i> , 2013 , 37, 819-30	9	78
60	Brain atrophy and lesion load predict long term disability in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 1082-91	5.5	209
59	Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1175-81	5	75
58	Idiopathic inflammatory demyelinating diseases of the brainstem. <i>Seminars in Ultrasound, CT and MRI</i> , 2013 , 34, 123-30	1.7	6
57	Clinical impact of early brain atrophy in clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1878-86	5	71
56	Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 245-8	5	24
55	Risk acceptance in multiple sclerosis patients on natalizumab treatment. <i>PLoS ONE</i> , 2013 , 8, e82796	3.7	21
54	Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. <i>European Journal of Neurology</i> , 2012 , 19, 899-904	6	42
53	Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS. <i>Acta Neurologica Scandinavica</i> , 2012 , 126, 24-30	3.8	18
52	Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1193-6	5	19
51	Value of NMO-IgG determination at the time of presentation as CIS. <i>Neurology</i> , 2012 , 78, 1608-11	6.5	15
50	THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 627-37	4.3	67
49	Using the WHOQOL-DIS to measure quality of life in persons with physical disabilities caused by neurodegenerative disorders. <i>Neurodegenerative Diseases</i> , 2011 , 8, 178-86	2.3	15
48	A functional magnetic resonance proof of concept pilot trial of cognitive rehabilitation in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 457-67	5	76
47	Interferon βb for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up. <i>Archives of Neurology</i> , 2011 , 68, 1421-7		34
46	Brainstem lesions in clinically isolated syndromes. <i>Neurology</i> , 2010 , 75, 1933-8	6.5	136
45	A missense HTRA1 mutation expands CARASIL syndrome to the Caucasian population. <i>Neurology</i> , 2010 , 75, 2033-5	6.5	57
44	Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS. <i>Journal of Neurology</i> , 2010 , 257, 742-6	5.5	18

43	Development and pilot phase of a European MS register. <i>Journal of Neurology</i> , 2010 , 257, 1620-7	5.5	9
42	Measures in the first year of therapy predict the response to interferon beta in MS. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 848-53	5	182
41	Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 1459-65	5	26
40	A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. <i>Archives of Neurology</i> , 2009 , 66, 587-92		96
39	A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 1195-205	5	74
38	Plasma levels of 15d-PGJ are not altered in multiple sclerosis. <i>European Journal of Neurology</i> , 2009 , 16, 1197-201	6	5
37	Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2009 , 282, 120-4	3.2	22
36	New treatment measurements for treatment effects on relapses and progression. <i>Journal of the Neurological Sciences</i> , 2008 , 274, 80-3	3.2	5
35	Mapping the brain pathways of declarative verbal memory: Evidence from white matter lesions in the living human brain. <i>NeuroImage</i> , 2008 , 42, 1237-43	7.9	79
34	Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 455-64	5	46
33	Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. <i>Neurology</i> , 2008 , 70, 1079-83	6.5	265
32	Very early scans for demonstrating dissemination in time in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 631-5	5	15
31	Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. <i>Annals of Neurology</i> , 2008 , 63, 790-3	9.4	83
30	Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 1076-82	5.5	52
29	Normal-appearing brain t1 relaxation time predicts disability in early primary progressive multiple sclerosis. <i>Archives of Neurology</i> , 2007 , 64, 411-5		63
28	Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006 , 77, 40-5	5.5	55
27	Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study. <i>Archives of Neurology</i> , 2006 , 63, 1175-80		135
26	Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006 , 77, 1036-9	5.5	54

25	Variations in chemokine receptor and cytokine expression during pregnancy in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 421-7	5	29
24	Baseline MRI predicts future attacks and disability in clinically isolated syndromes. <i>Neurology</i> , 2006 , 67, 968-72	6.5	209
23	Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2006 , 108, 456-60	2	30
22	Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study. <i>Journal of Neurology</i> , 2006 , 253, 224-30	5.5	63
21	Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. <i>Brain</i> , 2005 , 128, 1454-60	11.2	123
20	Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. <i>Neurology</i> , 2005 , 65, 633-5	6.5	52
19	Is inflammation important in early PPMS? a longitudinal MRI study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005 , 76, 1255-8	5.5	55
18	Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. <i>Archives of Neurology</i> , 2005 , 62, 569-73		94
17	Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 413-6	5	22
16	Decreased MMP-9 production in primary progressive multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 376-80	5	19
15	Specificity of Barkhof criteria in predicting conversion to multiple sclerosis when applied to clinically isolated brainstem syndromes. <i>Archives of Neurology</i> , 2004 , 61, 222-4		27
14	Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. <i>NeuroImage</i> , 2004 , 22, 353-9	7.9	74
13	Unconventional therapy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 320-2	5	15
12	Clinically definite multiple sclerosis after radiological Schilder-like onset. <i>Journal of Neurology</i> , 2003 , 250, 871-3	5.5	5
11	Myelopathy in seronegative Sjögren syndrome and/or primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 256-9	5	20
10	APS and the brain. <i>Lupus</i> , 2003 , 12, 877-82	2.6	41
9	Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 39-43	5	42
8	The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta. <i>Journal of Neuroimmunology</i> , 2002 , 130, 194-201	3.5	68

7	Polyglandular autoimmune syndrome type II and multiple sclerosis. <i>Journal of Neurology</i> , 2001 , 248, 330-5	9
6	Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. <i>Annals of Neurology</i> , 2001 , 49, 408-411	9.4 30
5	Transient ischaemic attack: a common initial manifestation of cardiac myxomas. <i>European Neurology</i> , 2001 , 45, 165-70	2.1 27
4	Response to botulinum toxin in a case of rigid spine syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001 , 71, 564-5	5.5 5
3	Mitral papillary fibroelastoma as a cause of cardiogenic embolic stroke: report of two cases and review of the literature. <i>European Journal of Neurology</i> , 2000 , 7, 449-53	6 31
2	Lower motor neuron disease in a HIV-2 infected woman. <i>Journal of Neurology</i> , 2000 , 247, 718-9	5.5 13
1	Daclizumab to treat multiple sclerosis399-404	